ELOX
Income statement / Annual
Last year (2022), Eloxx Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Eloxx Pharmaceuticals, Inc.'s net income was -$36.07 M.
See Eloxx Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
06/30/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$75,000.00 |
$75,000.00 |
$100,000.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$75,000.00
|
$75,000.00
|
$100,000.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
| Research and Development Expenses |
$23.73 M
|
$45.57 M
|
$14.59 M
|
$26.35 M
|
$20.49 M
|
$16.40 M
|
$733,661.00
|
$2.18 M
|
$4.57 M
|
$3.34 M
|
| General & Administrative Expenses |
$10.69 M
|
$20.45 M
|
$14.85 M
|
$24.21 M
|
$26.48 M
|
$2.70 M
|
$1.46 M
|
$1.41 M
|
$2.74 M
|
$2.61 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.69 M
|
$20.45 M
|
$14.85 M
|
$24.21 M
|
$26.48 M
|
$2.70 M
|
$1.46 M
|
$1.41 M
|
$2.74 M
|
$2.61 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$34.42 M
|
$66.02 M
|
$29.44 M
|
$50.56 M
|
$46.97 M
|
$19.10 M
|
$2.14 M
|
$3.79 M
|
$7.74 M
|
$7.02 M
|
| Cost And Expenses |
$34.42 M
|
$66.02 M
|
$29.44 M
|
$50.56 M
|
$46.97 M
|
$19.10 M
|
$2.14 M
|
$3.79 M
|
$7.74 M
|
$7.02 M
|
| Interest Income |
$274,000.00
|
$8,000.00
|
$337,000.00
|
$1.07 M
|
$601,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$1.95 M
|
$1.26 M
|
$1.41 M
|
$1.62 M
|
$7,000.00
|
$43,000.00
|
$265,203.00
|
$533.00
|
$2,767.00
|
$77,438.00
|
| Depreciation & Amortization |
$695,000.00
|
$960,000.00
|
$571,000.00
|
$559,000.00
|
$216,000.00
|
$39,000.00
|
$44,075.00
|
$93,394.00
|
$177,074.00
|
$349,656.00
|
| EBITDA |
-$33.37 M |
-$66.02 M |
-$33.46 M |
-$50.56 M |
-$46.15 M |
-$20.39 M |
-$4.59 B |
-$8.85 M |
-$17.88 M |
-$8.80 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-48.28
|
-99.82
|
-65.72
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-149.27
|
-241.02
|
-91.48
|
| Total Other Income/Expenses Net |
-$1.65 M
|
-$709,000.00
|
-$1.12 M
|
-$319,000.00
|
$502,000.00
|
-$824,000.00
|
-$2.24 M
|
$2.25 M
|
$12,951.00
|
-$77,438.00
|
| Income Before Tax |
-$36.07 M
|
-$66.73 M
|
-$34.58 M
|
-$50.87 M
|
-$47.06 M
|
-$21.21 M
|
-$6.84 M
|
-$8.95 M
|
-$18.06 M
|
-$9.23 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-119.31
|
-240.85
|
-92.25
|
| Income Tax Expense |
$0.00
|
$1.26 M
|
$1.41 M
|
$1.62 M
|
$122,000.00
|
$43,000.00
|
-$1.04 M
|
-$680,000.00
|
$2,767.00
|
$77,438.00
|
| Net Income |
-$36.07 M
|
-$66.73 M
|
-$34.58 M
|
-$50.87 M
|
-$47.19 M
|
-$21.21 M
|
-$5.80 M
|
-$8.27 M
|
-$18.06 M
|
-$9.23 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-110.24
|
-240.85
|
-92.25
|
| EPS |
-16.65 |
-38.15 |
-34.47 |
-53.46 |
-58.19 |
-57.33 |
-199.71 |
-325.47 |
-1002.37 |
-1347.73 |
| EPS Diluted |
-16.65 |
-38.15 |
-34.47 |
-53.46 |
-58.19 |
-57.33 |
-199.71 |
-325.47 |
-1002.37 |
-1347.73 |
| Weighted Average Shares Out |
$2.17 M
|
$1.75 M
|
$1.00 M
|
$951,579.00
|
$810,912.00
|
$370,022.00
|
$29,024.00
|
$25,403.00
|
$18,021.00
|
$6,845.00
|
| Weighted Average Shares Out Diluted |
$2.17 M
|
$1.75 M
|
$1.00 M
|
$951,579.00
|
$810,912.00
|
$370,022.00
|
$29,024.00
|
$25,403.00
|
$18,021.00
|
$6,845.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
